Related Experiment Videos
Reduced prostacyclin activity in systemic lupus erythematosus
Annals of the Rheumatic Diseases
|October 1, 1980
Summary
Plasma from some systemic lupus erythematosus (SLE) patients inhibited prostacyclin release, a key platelet aggregation inhibitor. This finding in SLE patients may relate to thrombotic lesions.
Area of Science:
- Cardiovascular biology
- Immunology
- Hematology
Background:
- Prostacyclin is a crucial inhibitor of platelet aggregation, normally released from vascular tissues like rabbit aorta.
- Systemic lupus erythematosus (SLE) is an autoimmune disease associated with an increased risk of thrombotic events.
Observation:
- Plasma from 2 SLE patients significantly inhibited prostacyclin release when incubated with fresh rabbit aorta.
- Plasma from 22 other SLE patients and 40 healthy controls exhibited normal prostacyclin release activity.
Findings:
- A subset of SLE patients demonstrated impaired prostacyclin activity in their plasma.
- The absence of prostacyclin activity did not correlate with the clinical severity of SLE in the affected patients.
Implications:
- This impaired prostacyclin activity in certain SLE patients may contribute to their thrombotic complications.
- Further research is warranted to explore the link between SLE, prostacyclin dysfunction, and thrombosis.